Update: DBV Technologies Follow-Up Study of Viaskin® Peanut Shows Significant Increase in Peanut Consumption and Treatment Benefit in Peanut Allergic Children

Findings support Viaskin® Peanut’s efficacy, compliance and safety profile

After 24 months, 80% of treated children respond to Viaskin Peanut 250 microg

12-month response rate in treatment-naïve patients consistent with previously-reported results

On track to start Phase III trial in 4Q 2015

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:DBVT), a clinical-stage specialty biopharmaceutical company,  today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy. The Viaskin Peanut patch is the company’s lead product candidate, which is based on epicutaneous immunotherapy (EPIT®), a proprietary technology platform that can deliver biologically active compounds to the immune system through intact skin without allowing compound passage into the blood. OLFUS is an ongoing, open-label, follow-up study to VIPES, the company’s Phase IIb clinical trial with Viaskin Peanut. DBV previously reported positive results from VIPES in September 2014, and is on track to begin a Phase III clinical trial, ‘PEPITES’, with Viaskin Peanut 250 microg in children (ages 4-11) in the fourth quarter of 2015.

Read more:

courtesy of Nasdaq